MedPage Today on MSN
For Your Patients: Understanding Relapse and What It Means for Your Multiple Myeloma
Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...
The FDA has approved daratumumab and hyaluronidase (DARA SC; Darzalex Faspro, Janssen Biotech) for adults with high-risk ...
A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...
Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results ...
For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...
MedPage Today on MSN
Unusual Adverse Events After Treatment for Relapsed/Refractory Multiple Myeloma
The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies ...
For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...
A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...
The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...
The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...
Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients ...
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback